Roquefort Therapeutics (LON:ROQ) Trading Down 10.5% – Here’s Why

Shares of Roquefort Therapeutics plc (LON:ROQ) were down 10.5% during mid-day trading on Wednesday . The stock traded as low as GBX 2.32 ($0.03) and last traded at GBX 2.33 ($0.03). Approximately 1,770,633 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 2,032,882 shares. The stock had previously closed at GBX 2.60 ($0.03).

Roquefort Therapeutics Stock Performance

The firm’s 50 day simple moving average is GBX 3.76 and its 200-day simple moving average is GBX 3.91. The company has a market cap of £3.05 million, a price-to-earnings ratio of -1.98 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Insider Buying and Selling

In related news, insider Stephen Paul West purchased 400,000 shares of Roquefort Therapeutics stock in a transaction on Tuesday, February 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,081.06). 60.40% of the stock is currently owned by company insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.